5-苯并呋喃-2-基-1H-吲唑 | 885272-61-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 2-芳基苯并呋喃类黄酮
• 中文名称: 5-苯并呋喃-2-基-1H-吲唑
• 英文名称: 5-Benzofuran-2-YL-1H-indazole
• 英文别名: 5-(1-benzofuran-2-yl)-1H-indazole
• CAS: 885272-61-7
• 化学式: C₁₅H₁₀N₂O
• 分子量: 234.25
• InChiKey: SEOACZWIEFXVRE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.8
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF<br/>[FR] NOUVEAUX COMPOSÉS MODULATEURS DU MÉTABOLISME CELLULAIRE ET LEURS UTILISATIONS
  申请人：CRESCENTA BIOSCIENCES

  公开号：WO2021150645A1

  公开（公告）日：2021-07-29

  A class of compounds that bind to fatty acid binding protein (FABP4) and modulate adipocyte metabolism to drive enhanced glucose utilization, as well as pharmaceutical compositions comprising the class of compounds, in combination with a pharmaceutically acceptable diluent or carrier, and optionally, further in combination with a therapeutically active agent, and the use of these compounds in medicine and for the preparation of a medicament in the treatment of disorders acting on the FABP4.

  一类化合物，能够结合到脂肪酸结合蛋白（FABP4）并调节脂肪细胞代谢以促进增强葡萄糖利用，以及包含该类化合物的药物组合物，与药用辅料或载体相结合，并可选地进一步与治疗活性剂相结合，以及这些化合物在医学上的应用和用于制备治疗作用于FABP4的疾病的药物。
• Novel 2-Heteroaryl Substituted Benzothiophenes and Benzofuranes 709
  申请人：Arzel Erwan

  公开号：US20080221149A1

  公开（公告）日：2008-09-11

  The present invention relates to novel 2-heteroaryl substituted benzothiophene and benzofuran derivatives, precursors thereof, and therapeutic uses of such compounds, having the structural formula (Ia) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel 2-heteroaryl substituted benzothiophene and benzofuran derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measureing clinical efficacy of Alzheimer's disease therapeutic agents.

  本发明涉及新型2-杂环芳基取代苯并噻吩和苯并呋喃衍生物，其前体以及这些化合物的治疗用途，具有如下结构式(Ia)： 以及它们的药用盐、组合物和使用方法。此外，本发明涉及适用于在活体患者中成像淀粉样沉积物的新型2-杂环芳基取代苯并噻吩和苯并呋喃衍生物，它们的组合物、使用方法以及制备这类化合物的过程。更具体地，本发明涉及一种在体内成像脑部淀粉样沉积物的方法，以允许在死前诊断阿尔茨海默病，并测量阿尔茨海默病治疗药物的临床疗效。
• [EN] ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS<br/>[FR] UTILISATION ANTIVIRALE DE COMPOSÉS MODULANT LA FABP4
  申请人：CRESCENTA BIOSCIENCES

  公开号：WO2022010951A1

  公开（公告）日：2022-01-13

  A method for treating a viral disease in a subject comprising administering to said subject a therapeutically effective dose of one or more compounds that bind to fatty acid binding protein FABP4, with compounds described in the specification some having the general formula, Formula I-Formula XII, where W1 – W4 Z1-Z4 Z1 – Z5 X, Y, n, and R1 – R8 are as defined in the claims and description of embodiments. In examples, the ring Z contains Z1-Z4. In other examples, the ring Z contains Z1-Z5. (I)

  一种治疗受试者病毒性疾病的方法，包括向该受试者投予治疗有效剂量的一个或多个结合到脂肪酸结合蛋白FABP4的化合物，其中所述化合物在说明书中被描述，其中一些具有一般式I-式XII，其中W1-W4，Z1-Z4，Z1-Z5，X，Y，n和R1-R8如权利要求和实施例的描述中所定义。在示例中，环Z包含Z1-Z4。在其他示例中，环Z包含Z1-Z5。（I）
• [EN] NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF FOR THE TREATMENT OF VIRAL DISEASES<br/>[FR] NOUVEAUX COMPOSÉS MODULANT LE MÉTABOLISME CELLULAIRE ET LEURS UTILISATIONS POUR LE TRAITEMENT DE MALADIES VIRALES
  申请人：CRESCENTA BIOSCIENCES

  公开号：WO2022010948A1

  公开（公告）日：2022-01-13

  A class of compounds that bind to FABP4 and inhibit viral replication in cells, as well as pharmaceutical compositions comprising the class of compounds, in combination with a pharmaceutically acceptable diluent or carrier, and optionally, further in combination with an additional therapeutically active agent, and the use of these compounds in medicine and for the preparation of a medicament in the treatment of viral diseases. Formula I

  一类与FABP4结合并抑制细胞中病毒复制的化合物，以及包含该类化合物的药物组合物，与药学上可接受的稀释剂或载体结合，可选地，与另一种治疗活性剂结合，以及这些化合物在医学上的使用和用于制备治疗病毒性疾病的药物的公式I。
• Functionalized heterocycles as antiviral agents
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US11198693B2

  公开（公告）日：2021-12-14

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式（I）化合物或其药学上可接受的盐类： 其可抑制乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒 HBV 生命周期的功能，还可用作抗病毒剂。本发明进一步涉及包含上述化合物的药物组合物，用于给受 HBV 感染的患者用药。本发明还涉及通过施用包含本发明化合物的药物组合物治疗受试者 HBV 感染的方法。